Detalhe da pesquisa
1.
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.
ESMO Open
; 8(4): 101610, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37536254
2.
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.
ESMO Open
; 7(3): 100468, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35533427
3.
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
ESMO Open
; 7(2): 100403, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35272130
4.
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol
; 26 Suppl 5: v85-99, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26242182
5.
[Extramedullary blastic transformation revealed by a prolonged fever during the course of a 5q- syndrome]. / Fièvre prolongée au cours d'un syndrome 5q- révélant une transformation blastique extramédullaire.
Rev Med Interne
; 30(10): 886-9, 2009 Oct.
Artigo
em Francês
| MEDLINE | ID: mdl-19748163
6.
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Leuk Res
; 71: 82-88, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30025280
7.
Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes.
Leukemia
; 20(3): 463-70, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16408099
8.
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.
Leukemia
; 31(8): 1661-1670, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28484264
9.
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.
Leukemia
; 31(4): 882-888, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27740634
10.
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
Leukemia
; 31(4): 896-902, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27773929
11.
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.
Leukemia
; 31(12): 2726-2731, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28561069
12.
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.
Leukemia
; 30(4): 776-81, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26601783
13.
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
Leukemia
; 30(8): 1701-7, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27211272
14.
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.
Leukemia
; 30(5): 1018-24, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26854026
15.
Study of the thrombopoitin receptor in essential thrombocythemia.
Leukemia
; 11(11): 1821-6, 1997 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-9369413
16.
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT).
Leukemia
; 29(1): 20-6, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25151955
17.
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Leuk Lymphoma
; 22 Suppl 1: 149-60, 1996 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-8951786
18.
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.
Neth J Med
; 54(2): 46-62, 1999 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-10079679
19.
Defects of immune surveillance offer new insights into the pathophysiology and therapy of myelodysplastic syndromes.
Leukemia
; 21(11): 2237-9, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17957204
20.
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.
Leukemia
; 27(10): 2032-9, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23860450